“Spinal stimulation” does not identify one device, one procedure or one proven outcome. ARC-EX's FDA documents describe stimulation through skin-contact electrodes. The brain–spine research describes a more complex interface that incorporates recorded brain activity into control of stimulation. Those differences matter when interpreting a result. 1 2
The shared word stimulation is not enough to transfer an approval or finding from one system to another.
Separate delivery route from control strategy
Two questions organize the field more clearly. First, where are the stimulation components placed? Second, what controls the pattern of stimulation?
A device can differ on one axis without differing on every other axis. “Brain-controlled,” for example, describes a control relationship; “transcutaneous” describes delivery through the skin. The terms should not be treated as opposite ends of a single universal scale.
| Example or category | Delivery/control distinction | Evidence that cannot be assumed |
|---|---|---|
| ARC-EX | External skin-contact electrodes, programmed stimulation, task practice | Universal walking restoration or treatment of every injury |
| Implanted spinal-stimulation research | Stimulation supplied through implanted components in the described system | The same indication or benefit as an external device |
| Brain–spine interface | Brain activity contributes to controlling stimulation | Anatomical reconnection of the injured cord |
The table summarizes the device and study architectures in the linked primary records; it is not a complete inventory or a treatment ranking. 1 2
The outcome is as important as the hardware
A report about hand strength is not a report about walking. A movement achieved with a system active is not automatically proof of retained movement without it. A change in neurological classification is another question again.
The original ARC-EX review makes the distinction especially clear by stating limits on functional and neurological claims. 3
If a comparison ignores those outcomes, the reader can be left with an apparently simple contest between devices that were not tested for the same purpose. A more useful comparison preserves the actual task and population.
Why a home-use clearance is not a new universal indication
The November 2025 ARC-EX clearance permits the specified home-use setting with take-home exercises. Its intended strength-and-sensation population remains defined. 1
That is an operationally meaningful change, but it is not permission to infer any desired benefit from any home stimulator. Device identity, prescribed use and the clinical context remain relevant.
The ARC-EX report gives the actual regulatory record rather than a generalized “FDA approved spinal stimulation” statement.
Why no effectiveness ranking appears here
A ranking would need a shared question, comparable participants, measured benefits and harms, and enough evidence to support the difference. These selected documents do not supply such a head-to-head comparison.
The absence of a ranking is not an absence of useful information. The completed comparison identifies what each term means, which evidence belongs to it and why one result cannot be used to market another system.
Interpreting the next headline
A substantive update should state the device, route, control system, participant group and outcome. It should also identify whether the evidence concerns a new cohort, longer follow-up, a new setting or a regulatory change.
For example, broader home access and a new neurological benefit would be two different kinds of progress. A publication should not imply the second merely because the first occurred.
The brain–spine walking report and assistance-versus-recovery explainer complete the comparison. None of these pages provides stimulation parameters or an unsupervised treatment protocol.